Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

This is the first randomized trial directly comparing pulse-modulated Holmium:YAG laser and thulium fiber laser treatment of kidney stones during ureteroscopy.

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

The woman was in severe pain and discomfort, unable to focus on her job, eat, or sleep properly. She was exhausted, but had ...

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...